Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 30, 2012
Previous Article Next Article

Boron dipyrromethene (BODIPY)-based photosensitizers for photodynamic therapy

Author affiliations

Abstract

Photodynamic therapy (PDT) has shown promise as an effective treatment modality for cancers and other localized diseases, such as age-related macular degeneration and actinic keratosis. PDT relies on light, photosensitizer and oxygen as elements in its mechanism of action. BODIPY photosensitizers that have been under extensive study over the past decade have been demonstrated as a new class of photosensitizers. In this review, we attempt to summarize the decade-long study of BODIPY-based photosensitizers. We provide an overview of the superior photophysical properties possessed by BODIPY-based agents and the various synthetic strategies employed that have led to improved and selective and/or targeted photosensitizers.

Graphical abstract: Boron dipyrromethene (BODIPY)-based photosensitizers for photodynamic therapy

Back to tab navigation

Supplementary files

Article information


Submitted
09 Jul 2012
Accepted
06 Sep 2012
First published
07 Sep 2012

RSC Adv., 2012,2, 11169-11183
Article type
Review Article

Boron dipyrromethene (BODIPY)-based photosensitizers for photodynamic therapy

S. G. Awuah and Y. You, RSC Adv., 2012, 2, 11169
DOI: 10.1039/C2RA21404K

Social activity

Search articles by author

Spotlight

Advertisements